Overview

Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Heathy Subjects

Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
Phase 1, open label study to evaluate the effects of NST-1024 on the pharmacokinetics (PK) of caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam (and 1-hydroxymidazolam) in healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
NorthSea Therapeutics B.V.